SecBot SecBot
8-K ·Filed May 7, 2026

CURX

Curanex Pharmaceuticals Inc
NEUTRAL
Impact 5/10
Horizonmonths Processed5mo ago SEC0001493152-26-021658
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor CURX stock price for potential reverse stock split announcement or any catalyst to push price above $1.00 for 10 consecutive days. Delisting risk remains if compliance is not achieved by November 2, 2026.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
CURX ▼ -32.91% at T+60d
NEUTRAL call -32.91% · α vs SPY -36.74% · entry $0.3160 → $0.2120
Entry = T+0 close
May 7, 2026
via day close
T+1d
+2.22%
call +2.22% · α +1.39%
$0.3230
settled 6mo ago
T+5d
-0.32%
call -0.32% · α -1.82%
$0.3150
settled 6mo ago
T+20d
+3.16%
call +3.16% · α +0.03%
$0.3260
settled 5mo ago
T+60d
-32.91%
call -32.91% · α -36.74%
$0.2120
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Curanex Pharmaceuticals received a 180-day extension from Nasdaq until November 2, 2026, to regain compliance with the $1.00 minimum bid price requirement. The company previously failed to meet the initial compliance deadline of May 4, 2026, and plans to consider a reverse stock split if needed to cure the deficiency.

Key Facts

  • Nasdaq notified Curanex on May 5, 2026, of an additional 180-day compliance period ending November 2, 2026, to regain minimum bid price compliance.
  • The company's stock had a closing bid price below $1.00 for 30 consecutive business days as of November 5, 2025.
  • Curanex intends to cure the deficiency via a reverse stock split if necessary.
  • If compliance is not demonstrated by November 2, 2026, Nasdaq will initiate delisting proceedings.

Financial Impact

No direct financial impact disclosed; delisting risk could impair liquidity and access to capital.

stock pricelisting status

Risk Factors

  • Failure to regain compliance by November 2, 2026, could result in Nasdaq delisting.
  • A reverse stock split may be dilutive in perception and does not address underlying business fundamentals.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-021658
Document: 0001493152-26-021658-index-headers.html0001493152-26-021658
Document: 0001493152-26-021658-index.html0001493152-26-021658
Document: 0001493152-26-021658.txt0001493152-26-021658
7 reports for CURX
Performance horizon
Filters
Rows
Reports for CURX — sortable, filterable
TypeNow
Oct 19, 2026
7d ago
8-K
NEUTRAL ★ 4/10
$4.77awaiting T+20—$4.75 (−0.31%)
Aug 17, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$4.44 $4.37▼ −1.69%▼ −0.70%$4.75 (+6.98%)
May 14, 2026
23w ago
8-K
NEUTRAL ★ 3/10
$0.3130 $0.3210▲ +2.56%▲ +3.41%$4.75 (+1417.57%)
May 14, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$0.3130 $0.3210▲ +2.56%▲ +3.41%$4.75 (+1417.57%)
May 7, 2026
24w ago
8-K
NEUTRAL ★ 5/10
$0.3160 $0.3260▲ +3.16%▲ +0.03%$4.75 (+1403.16%)
Apr 2, 2026
29w ago
8-K
NEUTRAL ★ 3/10
$0.4900 $0.4170▼ −14.90%▼ −24.77%$4.75 (+869.39%)
Mar 30, 2026
30w ago
Press Release
NEUTRAL ★ 3/10
$0.5110 $0.4300▼ −15.85%▼ −25.27%$4.75 (+829.55%)
Showing 7 of 7

US Market Status

Market Open — Closes in 4h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026